We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Single-Molecule PCR and the Future of Quantitative Molecular Analysis

Abstract illustration of a colorful DNA double helix. The DNA is glowing on a black background.
Credit: iStock.
Read time: 4 minutes

Accurate molecular quantification is central to translational research and clinical monitoring, particularly as the number of clinically relevant biomarkers continues to expand.


Established approaches, including quantitative polymerase chain reaction (qPCR), digital PCR (dPCR), and next-generation sequencing (NGS), each offer distinct advantages, but differences in how molecules are measured can affect sensitivity, standardization, and workflow complexity.


As researchers seek to monitor increasingly diverse molecular targets, there is growing interest in approaches that provide quantitative measurements across a broad dynamic range while maintaining reproducibility between experiments and laboratories.


Technology Networks recently spoke with Dr. Christina Fan, founder and CTO of Countable Labs, about the differences between qPCR, dPCR, and single-molecule PCR, and the future of quantitative molecular analysis.


In this interview, Fan discusses the rationale behind direct molecular counting and demonstrates solutions for pain points across minimal residual disease (MRD) monitoring, liquid biopsy, and cell and gene therapy (CGT) manufacturing.

Anna MacDonald (AM):

How do qPCR, dPCR, and single-molecule PCR compare as approaches to molecular quantification, and what unmet needs in existing methods motivated the development of Countable PCR?


Christina Fan, PhD (CF):

These are three philosophies of counting, and hematology-oncology (heme-onc) monitoring exposes the limits of each.


qPCR infers quantity from an amplification curve—it leans on standard curves and efficiency, is largely single-plex, and it varies lab to lab, which is why the field had to build an entire International Scale just to make chronic myeloid leukemia (CML) results comparable when testing for BCR::ABL1.


Digital PCR provides absolute counts by partitioning, but conventional systems have only tens of thousands of partitions, so molecules share compartments, and you fall back on statistical correction. As a result, multiplexing and dynamic range stay limited.


NGS brings scale, along with the caveat of amplification bias, complex workflows, and turnaround times that aren’t conducive to routine monitoring needs. Meanwhile, the list of clinically meaningful variants keeps growing—fusion isoforms, partner genes, co-mutations. I wanted a way to count targets of this growing list directly, from a limited sample, in a single reaction.


High-color single-molecule PCR checks all the boxes: ~30 million partitions put every target molecule on its own, and many optical colors—used in combination— can be used to resolve many targets at once. You count; you don't estimate; and you get breadth without sequencing.



AM:
A key distinction of Countable PCR is the ability to directly count molecules rather than infer quantities through amplification curves or statistical models. Why is this shift important, and what new biological questions does it enable researchers to address?

CF:

In biology, accurate counting is truth, and every prior method puts a layer between you and that count—qPCR infers from a curve, digital PCR corrects with statistics, and even sequencing, which I helped pioneer as a counting tool, reports estimates due to bias and library loss. In heme-onc, that layer is expensive: rare fusion transcripts and low-level residual disease are exactly where estimation breaks down, contributing to screening and monitoring issues. Our platform can really make an impact here.


When you count single molecules directly, the number is the measurement, so you can see the small, real changes that matter in monitoring—a rising fusion transcript, an emerging resistance mutation, a shift others would dismiss as noise. And because we read many colors at once, you can ask those questions across many variants in the same tube, rather than one marker at a time.



AM:
Why is the ability to accurately quantify both rare and abundant targets within the same reaction valuable?

CF:

This was a design goal from the start, and in heme-onc it's the everyday problem: you're measuring a rare fusion transcript against an abundant control gene, or a low-frequency mutation against wild-type. A six-log dynamic range lets you see both in one reaction—the rare signal isn't lost, and the abundant one doesn't saturate the readout. The sample becomes its own control, giving you internal normalization and absolute copy numbers in a single tube.


With high-color multiplexing, “rare and abundant” becomes “many rare and abundant”—you can track a panel of fusions, isoforms, and co-mutations together. That's what real monitoring across CML and acute myeloid leukemia (AML) actually requires.



AM:
How can direct molecule counting improve confidence in quantitative results across experiments, operators, and laboratories?

CF:

Reproducibility is where inference-based methods can fail, and BCR::ABL1 testing in CML is the clearest example: because qPCR varies, an entire International Scale—with conversion factors and reference reagents—had to be built just to make results comparable across labs, and even then, variability persists.


Direct counting makes comparability native: a count is a count, across operators, instruments, sites, and days. In our published work, a highly multiplexed assay held chromosome-ratio coefficients of variation between roughly 0.3 and 0.65% across different users and instruments. Bring that to heme-onc residual-disease monitoring, and you get standardization by counting, not by calibration—which is exactly what deep, cross-site monitoring needs.



AM:
Which applications stand to benefit most from direct molecular counting, and where do you see the greatest opportunities in areas such as liquid biopsy, MRD, or CGT?

CF:

The clearest near-term opportunity is heme-onc residual disease monitoring: it demands depth, reproducibility, and standardization at once, and the variant list keeps growing—from BCR::ABL1 in CML to KMT2A and NPM1 in AML. High-color single-molecule PCR is built for that: many variants, counted absolutely, in one reaction, reproducibly across labs.


The techniques extend naturally to other MRD applications and to liquid biopsy, where you're counting a minority tumor fraction against a background of normal cell-free DNA—the same minority-signal problem I worked on in prenatal testing.


Another application I'm especially excited about, though, is CGT manufacturing. A CGT product is characterized by a long list of separate assays—vector copy number, transgene titer, genome integrity, residual host-cell and plasmid DNA, and contaminants.


Because we count many colors at once, you can interrogate all targets of interest in a single reaction: tile multiple loci across the vector genome and confirm they're present in equal stoichiometry—directly assessing genome integrity—while simultaneously quantifying the transgene, the copy number, and residual-DNA impurities. In one reaction, with absolute counts and no standard curves, you get the whole picture of a manufacturing sample: identity, integrity, and purity together.


Across all of these applications, the thread is the same—an estimate isn't good enough; you need the counts, across many targets at once.


AM:
How do you expect molecular measurement technologies to evolve over the next decade? 

CF:

I think the field over-rotated toward “sequence everything,” and the pendulum is swinging back toward purpose-built, direct measurement—the recognition that you don't need to sequence to count.


In heme-onc specifically, I expect monitoring to move from centralized sequencing cores to local labs and accessible instruments; from one-time genotyping to serial, longitudinal tracking, where reproducibility is everything; and toward assays that cover a growing variant list in a single reaction instead of many reactions.


High-color, absolute, single-molecule measurement fits that trajectory—counts instead of estimates, and breadth without bioinformatics. AI will keep advancing interpretation, and we are very well set up to generate high-quality datasets for this new regime of AI-backed interpretation.


The one constraint that won't change is biology: you can't count molecules that aren't in the sample—so the real frontier is counting every one you're given, across as many targets as possible.



This article was produced under Technology Networks' AI Editorial Policy.
Google News Preferred Source Add Technology Networks as a preferred Google source to see more of our trusted coverage.